AI protein design: what’s funding like now?

All funding deals in the AI protein design market over the last 24 months

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the AI protein design market.

Is the AI protein design market actually healthier than a year ago?

The AI protein design funding market is stronger today for established companies, but the sharp decline in first-time financings raises serious questions about its overall health.

We counted 34 financing events involving 29 companies in the latest 12 months, compared with 27 deals involving 25 companies in the previous period. The median disclosed round increased from $10 million to $23.2 million, showing that companies are generally securing larger investments.

But the improvement has been uneven. First financings fell from eight to just three, while follow-on rounds increased from 19 to 31. Much of the additional money went to companies already developing established platforms or therapeutic pipelines, including Chai Discovery, BigHat Biosciences, and Syneron Bio.

This is encouraging for companies that have moved beyond their earliest development stages. For founders trying to secure their first institutional financing, the picture is considerably weaker.

Funding indicator	Previous 12M	Current L12M	Change
Total financing deals	27	34	+25.9%
Unique funded companies	25	29	+16.0%
Recorded capital	$495.39M	$1,476.73M	+198.1%
Median disclosed round	$10.0M	$23.2M	+132.0%
First financings	8	3	-62.5%
Follow-on financings	19	31	+63.2%
Later-stage deal share	14.8%	29.4%	+14.6 pp
Capital excluding rounds above $50M	$292.39M	$362.73M	+24.1%

Is AI protein design funding really booming, or are a few giant rounds inflating the numbers?

AI protein design funding is growing, but the nearly 200% jump in capital makes the market look much stronger than it is for most companies.

Total recorded financing increased from $495.39 million to approximately $1.477 billion. Once we remove transactions above $50 million, however, the increase falls to 24.1%.

Of the roughly $981 million in additional funding, only about $70 million came from the pool of transactions worth $50 million or less.

Large rounds are doing most of the work. Eight current-period financings exceeded $50 million, compared with three previously. Four deals exceeded $100 million, whereas the previous period had none.

Still, there's a real improvement underneath those exceptional transactions. The median disclosed round more than doubled, and capital excluding rounds above $100 million increased 39.4%.

For companies capable of raising tens of millions of dollars, financing conditions have clearly improved. But the headline growth figure says relatively little about how easy it has become for smaller companies to raise money.

Is Chai Discovery responsible for most of the AI protein design funding increase?

Chai Discovery accounts for a remarkable share of recent AI protein design funding, although the market would still have grown substantially without its $400 million Series C.

The company announced the financing in July 2026 at a $3.8 billion valuation. Index Ventures led the investment alongside Kleiner Perkins, Sequoia Capital, and Dimension.

That single transaction represented 27.1% of all recorded capital during the latest 12 months.

Removing it leaves approximately $1.077 billion in financing, still more than twice the previous period's total.

What makes Chai particularly interesting is how quickly it raised money. The company announced a $130 million Series B in December 2025, followed by the $400 million Series C roughly seven months later.

During that period, Chai expanded its pharmaceutical relationships. Pfizer announced a license agreement involving Chai-3 in June 2026, while Novartis and argenx announced antibody-discovery collaborations in July. Chai also worked with Eli Lilly through its biologics-discovery programs.

These partnerships help explain why investors were prepared to finance such rapid expansion. Chai had moved from developing molecular-design models toward getting its technology used by major pharmaceutical companies.

Its success is exceptional, however. Chai's fundraising trajectory should not be treated as representative of the wider industry.

Are more AI protein design companies getting funded now?

AI protein design funding is reaching more companies than a year ago, although the increase is much smaller than the rise in total investment.

The number of funded businesses grew from 25 to 29, while financing events increased from 27 to 34.

A larger proportion of companies also completed multiple financings during the same 12-month period. We identified four such businesses, compared with two previously. Their share of funded companies rose from 8% to 13.8%.

Funding activity became more consistent, too. Every month in the current period contained at least one recorded financing, compared with two months without any deals previously. Median monthly activity increased from two transactions to 2.5.

Yet the additional financing events are partly explained by companies returning for more capital. The number of businesses able to secure investment has improved moderately; the much bigger change is how much investors are prepared to commit to selected companies.

Are investors still funding new AI protein design startups?

New AI protein design startups are having a much harder time appearing in the funding figures, even as previously financed companies attract record amounts of money.

Only three financing events were classified as first financings in the latest period, down from eight. Their share of total transactions fell from 29.6% to 8.8%.

The decline goes beyond deal count. Recorded first-financing capital dropped from $86.5 million to $13.06 million, while the median first financing fell from $10 million to $1.9 million.

Meanwhile, follow-on funding increased substantially. Previously financed companies secured 31 rounds worth approximately $1.464 billion, compared with 19 rounds totaling $408.89 million a year earlier.

One limitation is that our first-financing classifications depend on the financing histories we could establish. A deal classified as a company's first recorded financing may not always represent its first-ever external investment.

Even with that caveat, the decline is substantial. First-time fundraising looks considerably weaker, while established companies are attracting more support.

Financing measure	Previous 12M	Current L12M	Change
First-financing deals	8	3	-62.5%
First-financing share	29.6%	8.8%	-20.8 pp
First-financing capital	$86.50M	$13.06M	-84.9%
Median first financing	$10.00M	$1.90M	-81.0%
Follow-on deals	19	31	+63.2%
Follow-on share	70.4%	91.2%	+20.8 pp
Follow-on capital	$408.89M	$1,463.67M	+258.0%
Median follow-on financing	$8.85M	$29.00M	+227.7%

Are AI protein design investors playing it safer now?

AI protein design investors are increasingly backing companies with funding histories, established technology, and progress toward drug development.

Several changes point in that direction. The median age of funded companies increased from approximately three years to four. The share of later-stage transactions nearly doubled, while first financings became much less common.

BigHat Biosciences shows the kind of company attracting larger checks. Founded in 2019, it announced a $75 million Series C in September 2026 after years of building its automated protein-design platform and advancing proprietary drug candidates.

Its lead program, BHB810, had already entered Phase 1 clinical testing. That gave investors evidence of progress toward patients, alongside the company's experimental-data and AI capabilities.

Syneron Bio presents another example. Its $150 million Series B followed earlier investment rounds and a strategic collaboration with AstraZeneca.

Company age alone does not explain investor behavior. Chai, founded in 2024, secured one of the sector's largest rounds despite being relatively young.

The common factor is progress. Investors appear increasingly willing to write large checks when companies can demonstrate valuable technology, pharmaceutical relationships, or therapeutic-development achievements.

The financing patterns strongly favor businesses that have already passed important development and funding milestones, even if they cannot establish a universal change in investors' requirements.

Is AI protein design moving away from seed funding?

AI protein design funding has shifted sharply toward Series B and Series C, even though early-stage companies still account for most transactions.

Seed activity declined from 15 rounds to ten, while Series A increased from eight to twelve. Series B rose from four to seven deals, and three Series C transactions appeared after none in the previous period.

The capital distribution changed much more dramatically.

Seed and Series A together attracted 63.4% of recorded funding previously. Their combined share is now just 20.6%. Later-stage transactions account for 78.4%.

The median Series B round also increased from $52 million to $100 million.

There's still meaningful early-stage activity, with 22 Seed and Series A financings in the current period. But the biggest checks increasingly support companies developing larger platforms and more advanced therapeutic programs.

Financing stage	Previous deals	Current deals	Previous capital share	Current capital share
Seed	15	10	22.1%	3.3%
Series A	8	12	41.3%	17.3%
Series B	4	7	36.6%	43.2%
Series C	0	3	0%	35.2%
Unknown	0	2	0%	1.0%
Early stage total	23	22	63.4%	20.6%
Later stage total	4	10	36.6%	78.4%

Which AI protein design category is attracting the most money?

Antibody and binder design is currently the strongest part of the AI protein design funding market, with growth in both deal count and capital.

We recorded twelve antibody and binder-design financings in the latest period, double the previous six. Funding increased from $192.1 million to $883.07 million.

Chai's $400 million financing contributed heavily to the increase. BigHat's $75 million Series C and financing activity around Aureka show that investor interest extends beyond a single company, although Aureka's multi-tranche disclosures need careful treatment.

Peptide design presents a different picture. Capital jumped from $33.55 million to $291 million, despite deal count falling from five to four. Syneron's $150 million Series B and Peptilogics' $78 million financing accounted for most of that increase.

Research and synthetic-biology protein design also gained attention, with deals doubling from four to eight. Recorded funding changed little, however, partly because several financing amounts remain undisclosed.

Antibody design therefore has the clearest combination of more financing activity and more money being invested. Peptide design is attracting much bigger individual investments without a comparable increase in financing breadth.

Protein design category	Previous deals	Current deals	Previous capital	Current capital
Antibody & Binder	6	12	$192.10M	$883.07M
Peptide	5	4	$33.55M	$291.00M
Research & Synthetic Biology Proteins	4	8	$146.80M	$153.20M
Therapeutic Protein	4	5	$51.40M	$119.20M
Enzyme	6	2	$60.33M	$8.36M
Industrial Protein	2	3	$11.21M	$21.90M
All categories	27	34	$495.39M	$1,476.73M

Is AI enzyme design funding drying up?

AI enzyme design has experienced the sharpest funding slowdown of any protein-design category we tracked.

Deal count fell from six to two, a 66.7% decline. Recorded financing dropped from $60.33 million to $8.36 million, approximately 86% lower than in the previous period.

The contrast with antibody design is particularly striking. While antibody companies doubled their deal count and attracted several large financings, enzyme-design activity weakened considerably.

The wider research and synthetic-biology protein category also doubled its number of deals, suggesting that investors haven't simply abandoned all nontherapeutic applications.

The enzyme category is small enough that a single large round could change the comparison substantially. There isn't sufficient evidence to attribute the decline to specific problems with commercial adoption or technological progress.

For now, enzyme-design companies have attracted much less recorded financing while investment has grown in other parts of protein design.

Why are investors putting so much money into AI-designed peptides?

Investors are putting larger amounts into selected AI peptide companies because some are now financing serious drug-development programs, including clinical trials.

Syneron Bio announced in April 2026 that it had closed a $150 million Series B at the end of March. The financing supports its Synova macrocyclic-peptide discovery platform and the development of therapeutic candidates.

Syneron had already established a significant relationship with AstraZeneca. In March 2025, the companies announced a collaboration that included upfront and near-term milestone payments potentially totaling $75 million, additional development and commercial milestones, royalties, and an equity investment.

Peptilogics offers another example. Its $78 million Series B2, announced in October 2025, was intended to advance zaloganan, an investigational treatment for prosthetic joint infections, into a pivotal Phase 2/3 clinical trial. The company announced the enrollment of the first patient in March 2026.

These are expensive development programs with clinical and regulatory requirements. Investors are funding much more than the initial design of new peptides.

The category's capital growth is impressive, but heavily concentrated in these larger transactions. As seen in the table above, the number of financings actually decreased.

Are AI protein design startups raising money faster now?

A few AI protein design startups are raising successive rounds remarkably quickly, but we still lack enough evidence to say that fundraising has accelerated across the whole market.

Chai is the clearest case. Its $130 million Series B in December 2025 was followed by a $400 million Series C approximately seven months later. The company linked that rapid progression to improvements in its technology and growing pharmaceutical adoption.

Syneron also moved quickly through successive stages. In December 2025, it announced nearly $100 million raised across Series A and A+ financings, followed by its $150 million Series B closing in March 2026. The announcement dates are clear, although the exact timing of earlier underlying closes requires care.

These examples show that substantial additional capital is available when investors are convinced by a company's progress.

But reliable previous-round closing dates aren't available for every follow-on financing. That prevents a meaningful calculation of the typical time between rounds, or the percentage of companies raising again within one or two years.

Rapid fundraising is well documented among selected winners. Whether the average protein-design startup can raise money faster remains an open question.

Is AI protein design funding leaving Europe for the US and China?

AI protein design funding has shifted strongly toward the United States and China, while Europe has suffered a steep decline in recorded deal activity.

Europe went from twelve financings to four, reducing its share of total deals from 44.4% to 11.8%. Recorded capital fell from $228.08 million to just $18.67 million.

North America moved in the opposite direction, with deals increasing from eleven to eighteen. Every current-period North American financing was associated with a US company.

Asia-Pacific also recorded substantial growth, from three deals to ten. China accounted for seven current transactions, compared with two previously.

The funding amounts require more caution than the deal counts. Five of the ten current Asia-Pacific transactions lack disclosed amounts, so the region's recorded $215.76 million provides an incomplete view of its financing.

Europe's decline, however, is visible in both the number of deals and disclosed capital. The US has strengthened its position as the largest funding center, while China is becoming more prominent in financing activity.

Region	Previous deals	Current deals	Previous capital	Current capital
North America	11	18	$245.51M	$1,208.30M
Asia-Pacific	3	10	$15.20M	$215.76M
Europe	12	4	$228.08M	$18.67M
Middle East	1	2	$6.60M	$34.00M
Total	27	34	$495.39M	$1,476.73M
North America deal share	40.7%	52.9%	-	-
Asia-Pacific deal share	11.1%	29.4%	-	-
Europe deal share	44.4%	11.8%	-	-

Are pharmaceutical companies becoming more important to AI protein design funding?

Pharmaceutical companies and other strategic investors are playing a bigger recorded role in AI protein design financing, especially around businesses with technology that can feed into real drug-development programs.

We identified strategic participation in twelve current-period financings, compared with five previously. Their share of total deals increased from 18.5% to 35.3%.

The median disclosed financing involving strategic participation also increased from $12.5 million to $29 million.

BigHat's September 2026 financing included existing investors such as Amgen Ventures, Eli Lilly, and Merck Global Health Innovation Fund. The company's platform also has relationships with pharmaceutical groups including Johnson & Johnson and AbbVie.

Syneron's relationship with AstraZeneca is another example of how a strategic partnership can combine drug-discovery collaboration and equity investment.

Chai has also built relationships with Pfizer, Lilly, Novartis, and argenx. These agreements demonstrate commercial interest in its technology, although a pharmaceutical collaboration should never automatically be counted as an equity investment.

The growth in strategic participation is meaningful, even allowing for classification uncertainty. Investors with direct experience in pharmaceutical development are becoming more visible around companies seeking to turn computational protein design into useful therapeutic products.

Are more venture capital firms competing to invest in AI protein design?

More investors are appearing in AI protein design financing announcements, but we can't confidently say that competition for deals has increased across the sector.

Our research identified 50 distinct named lead-investor entries during the latest period, compared with 30 previously. Lead-investor information was available for 31 of 34 current transactions.

Large rounds attracted substantial syndicates. Chai's Series C brought together major technology and venture investors. BigHat secured backing from DFJ Growth, Premji Invest, and several existing pharmaceutical-related investors. Syneron's financing involved international life-sciences investors alongside Asian investment groups.

However, investor disclosures aren't standardized. Some announcements name only leads, while others include co-leads, returning shareholders, and additional participants.

We therefore shouldn't treat the increase in named investor entries as proof of a proportionate expansion in the total investor base.

Successful companies can assemble large, varied financing syndicates. Whether smaller protein-design startups are attracting more potential investors is much harder to establish.

Do AI protein design startups need clinical results to get funded now?

Clinical progress and experimental proof are becoming especially valuable in large AI protein design financings, although companies can still attract substantial investment before entering clinical trials.

BigHat provides one of the strongest examples. In September 2026, it announced that the first patient had been dosed in its Phase 1 trial of BHB810, an AI-designed antibody-drug conjugate targeting CDH17.

Later that month, Premji Invest explained why it co-led BigHat's $75 million Series C. The investor highlighted the company's ability to combine AI with automated experimental work and advance its own molecules toward patients.

Syneron's financing also supports movement toward clinical development. Peptilogics had progressed even further with zaloganan, beginning a Phase 2/3 trial in March 2026.

Chai follows a different route. Its commercial relationships with major pharmaceutical companies provide evidence of adoption without every AI-designed molecule needing to have reached clinical trials.

What investors want to see depends on the business. A therapeutic developer may need convincing preclinical or clinical results, while a discovery-platform company can demonstrate progress through experimental performance and pharmaceutical adoption.

Comparable milestone information isn't available for every round, so we can't calculate how many companies met each type of milestone. Still, major financing announcements increasingly connect investment to visible technical or development achievements.

What are AI protein design startups spending their funding on now?

Large AI protein design companies are increasingly raising money to expand research platforms, run experimental infrastructure, and advance drug candidates toward clinical development.

Chai said its $400 million Series C would support additional computing resources, data, research, and product development. The company also intends to bring its technology to more scientists working on difficult drug-discovery problems.

BigHat is combining platform development with proprietary therapeutics. Its Milliner system uses automated experimentation to generate biological data, while programs such as BHB810 require clinical trials and broader drug-development capabilities.

Syneron's $150 million financing has a similar dual purpose. The company plans to strengthen its Synova discovery platform while advancing therapeutic candidates.

Peptilogics shows how the spending can become more clinical as a program matures. Its $78 million financing supports a pivotal trial rather than an early computational-design demonstration.

Across these examples, the funding needs now extend well beyond software and model development. Companies are paying for experimentation, specialized scientific teams, and the expensive work needed to advance potential medicines.

Not every company provides a detailed breakdown of planned uses, so the exact market-wide spending shift cannot be measured. But the stated priorities of major financing recipients are consistent with a sector moving further into drug-development execution.

Is AI protein design funding becoming too concentrated?

AI protein design funding is highly concentrated in large rounds, and dependence on exceptionally big transactions has increased considerably.

The largest financing represented 27.1% of current recorded capital, compared with 14.7% previously. Transactions above $50 million accounted for 75.4% of funding, up from 41%.

Interestingly, concentration among the five largest transactions barely changed. Those deals accounted for approximately 60% of current funding, versus 58.6% previously.

The top ten also represented a similar share in both periods, at around 82%.

Funding was already concentrated among a relatively small number of businesses. The latest change is that the biggest financings have become much larger.

Chai's $400 million Series C illustrates the extreme end, while Syneron and BigHat show how substantial later-stage investments are becoming more common.

For investors tracking the sector, total funding growth now depends heavily on whether a small group of companies continues attracting unusually large checks.

For founders, the concentration reinforces the differences between well-established companies and those still trying to secure early capital.

Can we trust the AI protein design funding numbers?

The broad increase in AI protein design funding is well supported, but some precise comparisons remain sensitive to missing amounts, uncertain closing dates, and unusual financing structures.

We established usable disclosed or estimated amounts for 29 of 34 current transactions, compared with 25 of 27 previously. That leaves five current deals and two previous deals without usable financing amounts.

Some transactions also need special treatment. Caravel Bio's $1.9 million pre-seed financing has an uncertain closing date. Ukko's $45 million Series C was reported in 2026 but described as having closed during 2025.

Fable Therapeutics disclosed separate seed and Series A financings together, while Aureka's financing history includes multiple tranches that require care to avoid double counting.

These uncertainties can affect comparisons of monthly activity, stages, and individual company fundraising histories.

The largest confirmed transactions are better established. Chai publicly announced its $400 million Series C, Syneron confirmed the closing of its $150 million round, and BigHat announced its $75 million financing on the final day of the comparison period.

Our strongest conclusions therefore concern larger late-stage investments, increased follow-on activity, and the decline in recorded first financings. We have less confidence in market-wide fundraising speed and exact capital totals where undisclosed or cumulative amounts are involved.

The figures represent a consistent comparison of recorded financing, rather than audited totals covering every private transaction.

What really changed over the last 12 months?

AI protein design has become a much better-funded market for established companies.

The median disclosed round more than doubled, later-stage financing became much more common, and follow-on capital increased dramatically. Investors are willing to finance expensive development programs at a scale that was far less visible a year earlier.

The weakest part of the market is new startup funding.

First financings declined sharply despite an increase in the total number of funded companies. That's a concern for the sector's longer-term development, especially in a field where scientific breakthroughs can come from young research teams.

The spectacular capital increase hides a much smaller improvement underneath.

Total funding nearly tripled, but excluding rounds above $50 million leaves growth of roughly one-quarter. Record capital doesn't mean financing opportunities have improved equally for most AI protein design startups.

Antibody design is gaining the most convincing momentum.

Antibody and binder-design financing doubled in deal count, alongside substantial capital growth. Peptide companies attracted much larger checks without an increase in financing events, while enzyme design experienced a pronounced decline.

Investors are putting more weight on demonstrated progress.

Chai's pharmaceutical adoption, BigHat's clinical-stage programs, and Syneron's therapeutic-development plans help explain why selected businesses can raise much larger rounds. Investors increasingly have concrete scientific and commercial achievements to evaluate.

The geography of funding has changed substantially.

The United States remains the strongest center for recorded financing activity and capital. China has become more prominent in deal count, while Europe's financing activity has weakened considerably.

The next challenge is getting more new companies funded.

The market can now support larger platforms, extensive experimental programs, and more advanced therapeutic development. What it has yet to demonstrate is a comparable improvement in first-time funding opportunities.

Overall, AI protein design is becoming a more mature and capital-intensive market. It is stronger for companies that have already made meaningful progress, but the latest financing cycle offers much less evidence of improving conditions for new entrants.